Tumor Immune Equipment
-
based in CANADA
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while simultaneously enhancing immune modulation through the conditional activity of a natural immunomodulatory ...
-
Manufactured by Prellis Biologics, Inc.based in USA
and llama), immunogenicity evaluation, and in vitro tumor immune ...
-
Manufactured by NanoStringbased in USA
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status. Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler ...
-
by Genmab A/Sbased in DENMARK
to elicit an anti-tumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation, using inert DuoBody IgG1 antibody ...
-
Manufactured by MedGenome Inc.based in USA
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the ...
-
Manufactured by Akoya Biosciencesbased in USA
Unraveling the complex and dynamic tumor microenvironment requires the assessment of spatial relationships between tumor and immune cells. Multiplex imaging utilizing tumor and immunologic markers can reveal the spatial relationships between tumor and immune cells, leading to the discovery of ...
-
Manufactured by Mersana Therapeuticsbased in USA
of efficacy, delivery and tolerability. Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the anti-tumor activity of Immunosynthen STING-agonist ADCs involves the targeted activation of the STING pathway in both ...
-
Manufactured by MV BioTherapeutics SAbased in SWITZERLAND
Cancer immunotherapy has therapeutic efficacy in a limited number of patients. Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity. However, only a limited fraction of patients benefits from the therapeutic response obtained with these ...
-
based in GERMANY
As multi-mechanistic antitumor agents, oncolytic viruses are emerging to be potent immunotherapeutic treatment options in different tumor indications. Oncoytic viruses specifically replicate in tumor cells due to altered signalling pathways supporting the tumor’s immune esape, leaving open replication advantages for ...
-
based in FRANCE
Regulatory T cells (Tregcells) represents a cell population with strong immunosuppressive activities. In cancer patients, Treg cells can dampen protective immune responses against tumor antigens. Moreover, high infiltration by Treg cells has been associated with poor survival invarious types of cancer. Therapeutic strategiesto eliminateTreg ...
-
Manufactured by Scopus BioPharmabased in USA
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the activity of the STAT3 gene by way of RNA interference. CO-sTiRNA™ also stimulates TLR9 ...
-
based in SOUTH KOREA
OGB23501 is a first-in-class tri-specific tumor microenvironment (TME) immune activator, which simultaneously targets PD-1, CTLA-4, and VEGF. We aim to develop it as a potential backbone therapy for melanoma, NSCLC, HCC, and renal ...
-
based in GERMANY
parental platforms while minimizing risks factors. This results in an oncolytic virus platform with an excellent safety profile and effective replication kinetics. Tumor-selective replication leads to significant oncolytic activity, while fusion-based cell death adds to its potent immune-stimulatory properties. Together this results in tumor ...
-
Manufactured by Rubius Therapeutics, Inc.based in USA
RTX-321 is an allogeneic, off-the-shelf artificial antigen presenting cell (aAPC) therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I ...
-
Manufactured by Fate Therapeutics, Inc.based in USA
MICA and MICB (MICA/B) are stress proteins expressed on a broad range of solid and hematopoietic tumor cells and serve as an activation signal for NKG2D+ NK and T cells. However, MICA/B are frequently shed as an immune escape mechanism, preventing recognition and destruction of tumor cells by the immune system. Proteolytic ...
-
Manufactured by NanoStringbased in USA
The GeoMx Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of tumor biology, the tumor microenvironment, and the immune response. Profile RNA expression of over 1,800 genes simultaneously with spatial resolution from distinct regions of interest with a single tissue section using the GeoMx Digital Spatial ...
-
Manufactured by Adicet Biobased in USA
at harnessing the tumor specific immunity of gamma delta T cells. The Company believes that gamma delta T cells have a superior potential compared to alpha beta T cells to be active in both solid tumors and hematological ...
-
by CohBar, Inc.based in USA
Overexpression of the CXCR4 receptor in human tumors is associated with metastatic disease and poor survival. Inhibition of the CXCR4 receptor mobilizes immune cells, enhances the effects of chemotherapy and immunotherapy in various cancers, and reduces the development of metastatic tumors by blocking the ability of tumor cells ...
-
Manufactured by Elicio Therapeuticsbased in USA
to train T cells to target specific antigens, ELI-007 has the potential to generate tumor-specific immunity capable of eliminating BRAF-driven cancers. ...
-
based in USA
; method using proven immunostimulatory proteins. After intradermal administration, these modified vesicles deliver both immunostimulatory proteins, which act as adjuvants, and an array of patient-specific tumor-membrane antigens simultaneously to the immune system. This creates robust tumor-specific immunity that Metaclipse ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you